Ambagon Therapeutics

0 followers


Ambagon is discovering and developing small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins.

Industries

Headquarters

Stage

Employees

Links

Org chart

Scott Clarke

Collapse
Christian Ottmann
Co-Founder & Chief Technology Officer
Nancy Pryer
Chief Scientific Officer
Maarten Altelaar
Executive Director
Neil Richardson
Contract Manager
Tanja Meyer
VP & Head, Corporate Strategy & Business Development
Thomas Marty
Vice President Finance
Zhen Zhang
Sr. Director
Peter Dudek
Board Director